Antibody

Beone eyes Huahui Health’s trispecific HH-160 with $2B option deal

Thu, 30 Apr 2026 12:00:00 -0400

Beone Medicines Ltd. gained an exclusive option to develop cancer immunotherapy HH-160 worldwide in a deal potentially worth more than $2 billion for Huahui Health Ltd., the developer of the trispecific antibody.

Aventera raises funding for streptococcal infection program

Wed, 29 Apr 2026 09:00:00 -0400

Aventera Antibodies AB has successfully raised SEK14.5 million (US$15.6 million) in a funding round to support the preclinical development of the company’s lead drug candidate for life-threatening streptococcal infections.

Pilatus PLT-012 takes immunometabolic approach to reprogram TME

Tue, 28 Apr 2026 12:00:00 -0400

Pilatus Bio Inc. is working to address a major under-addressed target of current checkpoint inhibitors: metabolic stress within solid tumors. “Traditional immunotherapies release immune ‘brakes,’ but they do not address the underlying metabolic stress in tumors,” Pilatus CEO and cofounder Raven Lin said. “That’s why more than 60% of solid tumor patients do not respond to treatment.”

MICA/B GAALIE-mutant Ab shows preclinical efficacy in cancer models

Thu, 23 Apr 2026 09:00:00 -0400

The major histocompatibility complex class I polypeptide-related sequences A and B (MICA/B) are frequently expressed by cancer cells. In a recently published study, researchers from Icahn School of Medicine at Mount Sinai hypothesized that the therapeutic efficacy of anti-MICA/B antibodies could be enhanced through Fc optimization with three point mutations in the Fc region: G236A, A330L and I332E (GAALIE).

Netrin-1 inhibitor blocks chemo resistance in pancreatic cancer

Wed, 22 Apr 2026 12:00:00 -0400

Netris Pharma SA has delivered positive phase Ib data showing its first-in-class netrin-1 inhibitor NP-137 alleviates resistance to chemotherapy in pancreatic cancer. This could represent an important advance in treating these tumors, which are notoriously resistant to chemotherapy.

Biogen amasses full felzartamab rights with $850M TJ deal

Tue, 21 Apr 2026 12:00:00 -0400

Biogen Inc. has consolidated full global rights to felzartamab through an $850 million deal with TJ Biopharma Co. Ltd. April 20, closing the chapter on a complex 10-year license saga.

Fed Circuit hands headache patent win back to Teva

Tue, 21 Apr 2026 12:00:00 -0400

Ever since Teva Pharmaceutical Industries Ltd. sued Eli Lilly and Co. several years ago, claiming Lilly’s migraine drug, Emgality (galcanezumab), infringed its headache treatment patents, the two companies have been on a litigation rollercoaster.

Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’

Thu, 16 Apr 2026 12:00:00 -0400

The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically significant results do not read across to clinical benefit for patients with Alzheimer’s disease.

More of everything as Amazon moves into AI-driven drug R&D

Wed, 15 Apr 2026 09:00:00 -0400

Amazon is extending the reach of its “everything store” into drug R&D with the launch of an artificial intelligence-powered Bio Discovery business. The company has compiled a catalogue of 40-plus foundation models that have been trained on extensive biology datasets and are able to generate and evaluate drug molecules in silico. For now, this covers antibodies only, but it is intended to move into other modalities.

Regeneron enters radiopharma space via Telix deal

Tue, 14 Apr 2026 12:00:00 -0400

Regeneron Pharmaceuticals Inc. is entering the radiopharmaceutical space via a collaboration with Telix Pharmaceuticals Ltd. to jointly develop and commercialize next-generation radiopharmaceutical therapies.

More of everything as Amazon moves into AI-driven drug R&D

Tue, 14 Apr 2026 12:00:00 -0400

Regeneron enters radiopharma space via Telix deal

Mon, 13 Apr 2026 12:00:00 -0400

Synox en route to approval on positive phase III for TGCT

Mon, 13 Apr 2026 12:00:00 -0400

Synox Therapeutics Ltd. is preparing to file for FDA approval of emactuzumab in treating tenosynovial giant cell tumor (TGCT), after announcing positive top-line phase III results.

ACE2-nanobody fusion enables pan-sarbecovirus neutralization

Mon, 13 Apr 2026 09:00:00 -0400

SARS-CoV-2 utilizes the angiotensin-converting enzyme 2 (ACE2) receptor for cell entry and triggers ACE2 ectodomain shedding, which results in elevated vasoconstrictor angiotensin II (Ang-II) while depleting the protective Ang-(1-7). This effect can lead to acute respiratory distress syndrome, hypertension, acute kidney injury and organ damage.

Innovent presents data on IBI-3055 for autoimmune diseases

Fri, 10 Apr 2026 09:00:00 -0400

Innovent Biologics Inc. has presented preclinical data on IBI-3055, a trispecific T-cell engager for the treatment of autoimmune diseases. This trispecific antibody targets CD19, BCMA and CD3, and features an innovative 1+1+1 T-cell engager design with CD3 masking to minimize non-specific T-cell activation.

Five-drug VIPOR regimen shows promise in aggressive blood cancer

Tue, 07 Apr 2026 11:00:00 -0400

Deep molecular advances are enabling precision medicine for the field of hematology, Wyndham Wilson said during a plenary session at the 2026 Korean Society of Hematology International Conference March 26.

Korsana boosts Alzheimer’s work with reverse merger, $380M financing

Thu, 02 Apr 2026 09:00:00 -0400

Just over a month after emerging from stealth and disclosing a $150 million series A, Korsana Biosciences Inc. is making the leap to the public market via a merger with Cyclerion Therapeutics Inc. The agreement, which is backed by a $370 million private placement from Korsana’s investors, solidly positions the newly merged company as it heads toward the clinic with KRSA-028, a next-generation shuttled antibody targeting amyloid beta for the treatment of Alzheimer’s disease, and builds out a pipeline of neurodegenerative disease candidates.

Five-drug VIPOR regimen shows promise in aggressive blood cancer

Wed, 01 Apr 2026 12:00:00 -0400

Korsana boosts Alzheimer’s work with reverse merger, $380M financing

Wed, 01 Apr 2026 12:00:00 -0400

Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis

Tue, 31 Mar 2026 09:00:00 -0400

Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the treatment of atopic dermatitis.

More than two to tango: multispecifics at ESMO TAT

Fri, 27 Mar 2026 09:00:00 -0400

Multispecifics took center stage at this year’s ESMO TAT, emerging as one of the hottest trends in oncology research. Unlike traditional small-molecule drugs or monoclonal antibodies that typically target a single protein, multispecific compounds are engineered to harness multiple mechanisms of action within a single molecule. They orchestrate biology rather than just blocking it.

Idel raises $10.4M for intracellular pan-cancer drug delivery tech

Thu, 26 Mar 2026 12:00:00 -0400

Newco Idel Therapeutics GmbH has closed a €9 million (US$10.4 million) seed round to advance the development of a technology for delivery of cytotoxic drugs directly into the cytosol of tumor cells.

Kodiak’s Zenkuda sparkles in Glow2, BLA filing next

Thu, 26 Mar 2026 12:00:00 -0400

After previous setbacks with the program, investors largely brushed aside ocular-focused Kodiak Sciences Inc.’s anticipated phase III Glow2 data of tarcocimab tedromer in diabetic retinopathy (DR), so the positive top-line superiority results revealed March 26 caught many by surprise as it sets the company up for an accelerated multi-indication BLA submission.

Sanofi characterizes SAR-447610 for tauopathies

Wed, 25 Mar 2026 09:00:00 -0400

To overcome the limitations regarding conventional immunotherapy for treating tauopathies, researchers from Sanofi SA aimed to improve brain exposure and targeting pathological tau species by optimizing antibody design.

NIDB-3101: a new anti-tau biparatopic antibody for AD

Wed, 25 Mar 2026 09:00:00 -0400

Discoveric Bio Alpha Ltd. and collaborators have presented data regarding the rationale and design of NIDB-3101, a third-generation, human IgG1 anti-tau biparatopic antibody for the treatment of Alzheimer’s disease (AD).

Excalipoint closes $68.7M seed round for cancer T-cell engagers

Tue, 24 Mar 2026 12:00:00 -0400

Excalipoint Therapeutics Inc. launched with an oversubscribed $68.7 million seed financing round to advance a portfolio of T-cell engagers for solid tumors, marking one of the largest early stage financings in China biotech history.

Imbiologics crosses $1B market cap with Kosdaq debut

Tue, 24 Mar 2026 12:00:00 -0400

Imbiologics Corp.’s market capitalization reached ₩1.5 trillion (US$1.02 billion) on its Kosdaq debut March 20, as the biotech seeks to become a leading antibody drugmaker for autoimmune diseases.

Immutrin raises £65M series A to take another run at reversing amyloidosis

Tue, 24 Mar 2026 12:00:00 -0400

Newco Immutrin Ltd. has raised £65 million (US$86.9 million) in a series A to take its lead antibody program through to clinical proof of concept in transthyretin amyloid cardiomyopathy.

Financing at Immutrin to advance antibody for ATTR cardiomyopathy

Tue, 24 Mar 2026 09:00:00 -0400

Immutrin Ltd. has successfully raised £65 million ($87 million) in series A financing to advance its lead asset through clinical proof of concept in ATTR cardiomyopathy. Immutrin’s novel antibody selectively binds to amyloid fibrils and is engineered to deplete amyloid deposits in tissue via a targeted and coordinated immune response.

Milestone in CDR-Life and Boehringer Ingelheim partnership

Tue, 24 Mar 2026 09:00:00 -0400

CDR-Life Inc. has announced the achievement of the first preclinical milestone under its 2025 license agreement with Boehringer Ingelheim Pharma GmbH & Co. KG. This milestone underscores progress in the companies’ efforts to develop next-generation antibody-based therapies for autoimmune diseases.